Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 5, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 700,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,415.5 pence per share; lowest price paid was 1,384.5 pence per share.
- Treasury Holdings: Post-transaction, the Company holds 508,567,927 shares in Treasury (9.15% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 10.11% of total voting rights.
- Shares in Issue: 5,048,319,853 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 700,000 shares. The filing does not provide comparative data against prior periods for operational or financial performance metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure that the announcement does not constitute an offer to purchase securities. The shares purchased are intended to be held in Treasury.
Investor Verification Checklist
- Verify the total cost of the 700,000 share repurchase based on the disclosed price range.
- Confirm the impact of the 10.11% Treasury holding on total voting rights calculations.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.
- Review the Annual General Meeting minutes from May 5, 2011, to understand the full scope of the share buyback authority.